Berlin

• LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting
  2023-506784-33-00 5 2021-01-19 RET fusion-Positive NSCLC
• Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia Recruiting
  2024-513222-30-00 5 2020-02-20 Adolescent patient (13-17 years of age) with Schizophrenia
• A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generali … Recruiting
  2023-506688-32-00 5 2019-10-09 Primary Generalized Tonic-Clonic Seizures
• Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting
  2023-504694-20-00 9 2017-01-13 pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukem
• ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia Recruiting
  2024-512657-24-00 10 2014-03-27 Acute Lymphoblastic Leukaemia
• A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all … Recruiting
  2025-524580-21-00 10 2026-06-01 Grass pollen induced allergic rhinitis or rhinoconjunctivitis
• A study to learn more about the safety and effects of a new blood-thinning medicine, given alone and together with another blood-thinner, in … Recruiting
  2025-524043-12-00 3 2026-05-13 atrial fibrillation
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-034) Recruiting
  2024-516993-31-00 5 2026-05-11 Renal Cell Carcinoma
• EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting
  2025-523975-48-00 5 2026-05-08 Obesity
• A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting
  2023-509628-16-00 5 2026-05-07 Small Cell Lung Cancer (SCLC)
• GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/p … Recruiting
  2025-524328-24-00 3 2026-05-06 Ulcerative colitis
• A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-0 … Recruiting
  2025-524987-39-00 3 2026-05-04 Mild to Moderate Asthma
• Evaluating the clinical effectiveness of sodium bicarbonate for critically ill patients with metabolic acidosis and acute kidney injury Recruiting
  2025-523914-10-00 6 2026-04-30 Critical illness
• Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting
  2025-523974-18-00 5 2026-04-30 Obesity
• Pembro-FLASH Recruiting
  2022-501458-13-01 4 2026-04-29 Advanced Stage of Classic Hodgkin Lymphoma
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweigh … Recruiting
  2025-521384-12-00 2 2026-04-27 obesity
• A research study looking into how cagrilintide influences food intake and appetite in people with overweight or obesity Recruiting
  2025-524206-15-00 3 2026-04-24 Obesity
• A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK-2870-031) Recruiting
  2024-520014-22-00 5 2026-04-22 Locally advanced/metastatic urothelial carcinoma
• A study to assess NAV-240 in adult participants with Hidradenitis Suppurativa Recruiting
  2025-523557-33-00 4 2026-04-20 Moderate-to-Severe Hidradenitis Suppurativa
• A study in healthy men to test how well different doses of BI 3821001 are tolerated Recruiting
  2025-523899-23-00 1 2026-04-15 Healthy volunteer trial
• Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting
  2025-521456-35-00 4 2026-04-13 Mild to moderate asthma
• Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism Recruiting
  2025-522583-32-00 5 2026-04-13 Cold-Induced Urticaria and Symptomatic Dermographism
• A trial to learn how safe the combination of rilvegostomig and chemotherapy is and how well it works compared to durvalumab and chemotherapy … Recruiting
  2025-523085-24-00 5 2026-04-13 Biliary Tract Cancer

Showing 313–336 of 1,776 trials